Hispanolistic/E+ via Getty Images Investment Overview — Tango's Share Price Volatility Based On Competitor's Progress When I last covered Tango Therapeutics, Inc. (NASDAQ:TNGX) for Seeking Alpha, in January of this year, I gave the stock a “Buy” rating. I highlighted the fact that the Boston, Massachusetts-based biotech is one of only five companies to date — the others are Bristol Myers Squibb (BMY) (via its ~$5.8bn acquisition of Mirati Therapeutics), Amgen (AMGN), AstraZeneca (AZN), Johnson & Johnson ...